Trials / Completed
CompletedNCT00622609
Anti-MAG First Administration to Human
A Single-blind, Single Dose, Placebo Controlled, First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of Ascending Doses of GSK249320 in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
GSK249320 is a monoclonal antibody directed against myelin associated glycoprotein (MAG), a protein that inhibits axonal regeneration. GSK249320 acts as a MAG antagonist, and through this activity it is hypothesised that it will enhance recovery from neuronal degeneration following acute axonal injury, which occurs in spinal cord injury or stroke.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK249320A | GSK249320A intravenous infusion will be formulated as 100 milligrams/milliliters in 2 milliliters vials (filled to 1 milliliter), in phosphate buffer and delivered by a syringe and programmable pump. |
| DRUG | Placebo | Sodium chloride intravenous infusion will be given as matching placebo. |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2009-04-09
- Completion
- 2009-04-09
- First posted
- 2008-02-25
- Last updated
- 2017-07-21
Locations
2 sites across 2 countries: United States, Australia
Source: ClinicalTrials.gov record NCT00622609. Inclusion in this directory is not an endorsement.